Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods.
Elisabetta LoggiSilvia GalliGiovanni VitaleRoberto Di DonatoRanka VukoticElena GrandiniMarzia MargottiValeria GuarneriGiuliano FurliniClaudio GalliMaria Carla RePietro AndreonePublished in: PloS one (2017)
Monitoring during treatment with DAAs by using either HCV-RNA or HCV-Ag has only a limited predictive value for SVR. Since those assays are equivalent for identifying a virological relapse, HCV-Ag may be preferred from an economical and organizational perspective.